CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Turnstone Biologics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Turnstone Biologics Corp
9310 Athena Circle, Suite 300
Phone: (347) 897-5988p:347 897-5988 LA JOLLA, CA  92037  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 8/7/2025.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Turnstone Biologics Corp. is a biotechnology company. The Company was previously focused on developing new medicines to treat and cure patients with solid tumors through a differentiated approach to tumor infiltrating lymphocytes (TIL) therapy by selecting and expanding the most potent tumor-reactive T cells, which it refers to as Selected TILs for potential treatment across the majority of solid tumors. Its previous lead selected TIL candidate, TIDAL-01, was being developed for the treatment of colorectal cancer, head and neck cancer, and uveal melanoma and two investigator sponsored trials with H. Lee Moffitt Cancer Center and Research Institute, Inc., or Moffitt, across colorectal cancer, head and neck cancer, and uveal melanoma.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Treasurer, Company Secretary, Director Owen P.Hughes 50 8/11/2025 8/11/2025
President and Chief Executive Officer SammyFarah
Chief Executive Officer Sammy J.Farah 52 8/11/2025 10/1/2015
Chief Technology Officer BrianLichty
Chief Operating Officer SaryahAzmat 36 8/11/2025 11/1/2019

Business Names
Business Name
Myst Therapeutics, Inc.
Turnstone Biologics Inc.

General Information
Number of Employees: 3 (As of 6/30/2025)
Outstanding Shares: 23,140,691 (As of 8/5/2025)
Shareholders: 38
Stock Exchange: NASD
Federal Tax Id: 832909368
Fax Number: (302) 655-5049
Email Address: info@turnstonebio.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, August 15, 2025